Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
Retrieved on:
Wednesday, June 8, 2022
Science, Other Science, Research, Oncology, General Health, Health, Clinical Trials, Other Health, MBBS, Radiation, NPV, Cohort study, Radiation therapy, Multimedia, Cardiac catheterization, Cleveland Clinic, COVID-19, Molecular imaging, Radiopharmaceutical, Brain, Cancer, Interventional radiology, CEUS, PSA, Food, Positive, Magnetic resonance imaging, NPA, Solution, PPV, MD, MRCP, GE Healthcare, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Google Images, 3D ultrasound, Prostate cancer, Physician, Magnetic resonance, Radiology, Health, Neuro, Patient, Medicine, Acquisition, Department, Nuclear medicine, MRI, Emory, 18F, PET, Man, Neoplasm, PPA, Therapy, FDA, Emory University, Neuro-Oncology (journal), The Imaging Science Journal, Clinical trial, FRCR, Recurrence, Safety, Medical imaging, EU
The safety and efficacy of 18F-fluciclovine PET imaging for the detection of recurrent brain metastases has not been established.
Key Points:
- The safety and efficacy of 18F-fluciclovine PET imaging for the detection of recurrent brain metastases has not been established.
- Blue Earth Diagnostics has two clinical studies investigating the use of 18F-fluciclovine PET in the detection of recurrent brain metastases.
- The Phase 2 PURSUE trial is designed to establish image interpretation criteria for 18F-fluciclovine PET in detecting recurrent brain metastases.
- 18F-flucivlovine is under investigation by Blue Earth Diagnostics for potential use in adults for the detection of recurrent brain metastases in patients who have previously undergone radiation therapy.